Last reviewed · How we verify
Lumiliximab with FCR
Lumiliximab with FCR is a Small molecule drug developed by Biogen. It is currently in Phase 1 development.
At a glance
| Generic name | Lumiliximab with FCR |
|---|---|
| Sponsor | Biogen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (PHASE2)
- Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) (PHASE2)
- Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lumiliximab with FCR CI brief — competitive landscape report
- Lumiliximab with FCR updates RSS · CI watch RSS
- Biogen portfolio CI
Frequently asked questions about Lumiliximab with FCR
What is Lumiliximab with FCR?
Lumiliximab with FCR is a Small molecule drug developed by Biogen.
Who makes Lumiliximab with FCR?
Lumiliximab with FCR is developed by Biogen (see full Biogen pipeline at /company/biogen).
What development phase is Lumiliximab with FCR in?
Lumiliximab with FCR is in Phase 1.
Related
- Manufacturer: Biogen — full pipeline
- Compare: Lumiliximab with FCR vs similar drugs
- Pricing: Lumiliximab with FCR cost, discount & access